Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. MiMedx Group, Inc.
  6. Summary
    MDXG   US6024961012

MIMEDX GROUP, INC.

(MDXG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/10/2022 01/11/2022 01/12/2022 01/13/2022 01/14/2022 Date
5.47(c) 5.5(c) 5.14(c) 5.04(c) 5.12(c) Last
976 977 642 353 919 690 642 646 750 497 Volume
-2.84% +0.55% -6.55% -1.95% +1.59% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 255 M - -
Net income 2021 -19,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -28,4x
Yield 2021 -
Sales 2022 278 M - -
Net income 2022 -9,89 M - -
Net Debt 2022 - - -
P/E ratio 2022 -54,9x
Yield 2022 -
Capitalization 568 M 568 M -
Capi. / Sales 2021 2,23x
Capi. / Sales 2022 2,04x
Nbr of Employees 735
Free-Float 96,6%
More Financials
Company
MiMedx Group, Inc. is utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts for multiple sectors of healthcare. The Company is focused on addressing the needs of patients with acute and chronic non-healing wounds, and a late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions.... 
More about the company
Ratings of MiMedx Group, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about MIMEDX GROUP, INC.
01/10MIMEDX GROUP, INC. : Results of Operations and Financial Condition, Regulation FD Disclosu..
AQ
01/10MIMEDX Outlines Key Strategic Milestones for 2022
AQ
01/10MiMedx Group, Inc. Provides Revenue Guidance for the Financial Year 2022
CI
01/04MIMEDX to Participate at the H.C. Wainwright BioConnect Virtual Conference
AQ
2021MIMEDX to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021MIMEDX GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
2021MiMedx Lifts Adjusted Net Sales Outlook for FY21
MT
2021MIMEDX Outlines Long-Term Value Creation Strategy at Virtual Investor Day
AQ
2021Mimedx Group, Inc. to Provide New Details About Near- and Long-Term Growth Opportunitie..
CI
2021MIMEDX Announces Speakers for December 7 Investor Day
AQ
2021Top Premarket Decliners
MT
2021MIMEDX GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
2021MIMEDX to Present at the Piper Sandler 33rd Annual Healthcare Conference
GL
2021Peer Reviewed Study Demonstrates MIMEDX Dehydrated Human Amnion Chorion Membrane (dHACM..
AQ
2021Mimedx Group, Inc. Announces Publication of Peer-Reviewed Study in Facial Plastic Surge..
CI
More news
News in other languages on MIMEDX GROUP, INC.
01/10MiMedx Group, Inc. Fournit des prévisions de revenus pour l'exercice 2022
2021MiMedx relève ses prévisions de ventes nettes ajustées pour l'exercice 21
2021Earnings Flash (MDXG) Le GROUPE MIMEDX affiche un chiffre d'affaires de 63,1 millions d..
2021Les actions américaines commencent la semaine en grande partie à la hausse ; les Blue C..
2021Les actions du secteur de la santé continuent de s'enfoncer dans l'après-midi
More news
Analyst Recommendations on MIMEDX GROUP, INC.
More recommendations
Chart MIMEDX GROUP, INC.
Duration : Period :
MiMedx Group, Inc. Technical Analysis Chart | MDXG | US6024961012 | MarketScreener
Technical analysis trends MIMEDX GROUP, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 5,12 $
Average target price 14,50 $
Spread / Average Target 183%
EPS Revisions
Managers and Directors
Timothy R. Wright Chief Executive Officer & Director
Peter M. Carlson Chief Financial Officer
M. Kathleen Behrens Wilsey Chairman
David H. Mason Chief Medical Officer
Robert Benjamin Stein Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
MIMEDX GROUP, INC.-15.23%568
GILEAD SCIENCES, INC.-1.16%90 027
MODERNA, INC.-19.39%83 008
REGENERON PHARMACEUTICALS-2.58%64 327
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-3.88%52 722